Inhibrx, Inc. (NASDAQ:INBX) CEO Mark Lappe Purchases 9,500 Shares

Inhibrx, Inc. (NASDAQ:INBX) CEO Mark Lappe bought 9,500 shares of the firm’s stock in a transaction on Monday, September 9th. The shares were bought at an average price of $15.21 per share, for a total transaction of $144,495.00. Following the completion of the transaction, the chief executive officer now directly owns 657,048 shares in the company, valued at approximately $9,993,700.08. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Mark Lappe also recently made the following trade(s):

• On Friday, September 6th, Mark Lappe purchased 26,000 shares of Inhibrx stock. The shares were purchased at an average cost of $15.29 per share, with a total value of $397,540.00.
• On Tuesday, September 3rd, Mark Lappe purchased 20,000 shares of Inhibrx stock. The shares were purchased at an average cost of $15.81 per share, with a total value of $316,200.00.
• On Thursday, August 29th, Mark Lappe purchased 10,000 shares of Inhibrx stock. The shares were purchased at an average cost of $14.03 per share, with a total value of $140,300.00.

Inhibrx Stock Down 0.1 %

NASDAQ:INBX opened at $15.18 on Wednesday. The stock has a fifty day simple moving average of $13.50 and a 200-day simple moving average of $24.22. Inhibrx, Inc. has a 52-week low of $10.80 and a 52-week high of $18.95.

Inhibrx (NASDAQ:INBX) last announced its earnings results on Tuesday, August 13th. The company reported $125.48 earnings per share for the quarter, beating the consensus estimate of ($3.60) by $129.08. The firm had revenue of $0.10 million during the quarter. As a group, research analysts predict that Inhibrx, Inc. will post 87.5 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Vestal Point Capital LP acquired a new position in Inhibrx in the 4th quarter valued at about $58,140,000. Campbell & CO Investment Adviser LLC acquired a new position in Inhibrx in the 4th quarter valued at about $894,000. HCR Wealth Advisors acquired a new position in Inhibrx in the 4th quarter valued at about $239,000. Entropy Technologies LP acquired a new position in shares of Inhibrx during the 1st quarter valued at about $384,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Inhibrx by 7.0% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,920 shares of the company’s stock valued at $766,000 after acquiring an additional 1,426 shares during the last quarter. Institutional investors and hedge funds own 82.46% of the company’s stock.

Analysts Set New Price Targets

Separately, JMP Securities assumed coverage on Inhibrx in a research note on Tuesday, July 23rd. They set a “market perform” rating for the company.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.